246 related articles for article (PubMed ID: 18342010)
1. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.
Demotte N; Stroobant V; Courtoy PJ; Van Der Smissen P; Colau D; Luescher IF; Hivroz C; Nicaise J; Squifflet JL; Mourad M; Godelaine D; Boon T; van der Bruggen P
Immunity; 2008 Mar; 28(3):414-24. PubMed ID: 18342010
[TBL] [Abstract][Full Text] [Related]
2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
3. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
4. [Is it possible to correct the anergy of T lymphocytes that infiltrate tumors?].
van der Bruggen P
Bull Mem Acad R Med Belg; 2009; 164(5-6):183-91; discussion 192. PubMed ID: 20666149
[TBL] [Abstract][Full Text] [Related]
5. CTL activation is induced by cross-linking of TCR/MHC-peptide-CD8/p56lck adducts in rafts.
Doucey MA; Legler DF; Boucheron N; Cerottini JC; Bron C; Luescher IF
Eur J Immunol; 2001 May; 31(5):1561-70. PubMed ID: 11465114
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding.
Cole DK; Dunn SM; Sami M; Boulter JM; Jakobsen BK; Sewell AK
Mol Immunol; 2008 May; 45(9):2700-9. PubMed ID: 18243322
[TBL] [Abstract][Full Text] [Related]
7. Low binding capacity of murine tetramers mutated at residue 227 does not preclude the ability to efficiently activate CD8+ T lymphocytes.
Nugent CT; Renteria RO; Kuus-Reichel K; Kumar A
Immunol Lett; 2005 May; 98(2):208-15. PubMed ID: 15860220
[TBL] [Abstract][Full Text] [Related]
8. Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities.
Couedel C; Bodinier M; Peyrat MA; Bonneville M; Davodeau F; Lang F
J Immunol; 1999 Jun; 162(11):6351-8. PubMed ID: 10352247
[TBL] [Abstract][Full Text] [Related]
9. Spatial coordination of CD8 and TCR molecules controls antigen recognition by CD8+ T-cells.
Pecht I; Gakamsky DM
FEBS Lett; 2005 Jun; 579(15):3336-41. PubMed ID: 15913613
[TBL] [Abstract][Full Text] [Related]
10. Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells.
Lyons GE; Moore T; Brasic N; Li M; Roszkowski JJ; Nishimura MI
Cancer Res; 2006 Dec; 66(23):11455-61. PubMed ID: 17145893
[TBL] [Abstract][Full Text] [Related]
11. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
12. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size.
Liu SD; Tomassian T; Bruhn KW; Miller JF; Poirier F; Miceli MC
J Immunol; 2009 May; 182(9):5283-95. PubMed ID: 19380775
[TBL] [Abstract][Full Text] [Related]
13. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody.
Bernardeau K; Gouard S; David G; Ruellan AL; Devys A; Barbet J; Bonneville M; Chérel M; Davodeau F
Eur J Immunol; 2005 Oct; 35(10):2864-75. PubMed ID: 16163672
[TBL] [Abstract][Full Text] [Related]
14. Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality.
Yachi PP; Ampudia J; Zal T; Gascoigne NR
Immunity; 2006 Aug; 25(2):203-11. PubMed ID: 16872849
[TBL] [Abstract][Full Text] [Related]
15. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
[TBL] [Abstract][Full Text] [Related]
16. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
[TBL] [Abstract][Full Text] [Related]
17. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.
Calcinotto A; Filipazzi P; Grioni M; Iero M; De Milito A; Ricupito A; Cova A; Canese R; Jachetti E; Rossetti M; Huber V; Parmiani G; Generoso L; Santinami M; Borghi M; Fais S; Bellone M; Rivoltini L
Cancer Res; 2012 Jun; 72(11):2746-56. PubMed ID: 22593198
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.
Franciszkiewicz K; Le Floc'h A; Jalil A; Vigant F; Robert T; Vergnon I; Mackiewicz A; Benihoud K; Validire P; Chouaib S; Combadière C; Mami-Chouaib F
Cancer Res; 2009 Aug; 69(15):6249-55. PubMed ID: 19638592
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of cytotoxic T-lymphocyte activation by soluble CD8.
Sewell AK; Gerth UC; Price DA; Purbhoo MA; Boulter JM; Gao GF; Bell JI; Phillips RE; Jakobsen BK
Nat Med; 1999 Apr; 5(4):399-404. PubMed ID: 10202928
[TBL] [Abstract][Full Text] [Related]
20. IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells.
Broderick L; Brooks SP; Takita H; Baer AN; Bernstein JM; Bankert RB
Clin Immunol; 2006; 118(2-3):159-69. PubMed ID: 16271513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
